Abstract
Ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used by clinicians to manage ocular inflammation and pain following cataract surgery. Over the past decade, the US Food and Drug Administration has approved multiple topical NSAIDs for these purposes, including several reformulated products. One of these medications, bromfenac ophthalmic solution, has a long and extensive history, with proven efficacy and safety in patients following cataract surgery. The evolution of bromfenac ophthalmic solution over the years has involved either lowering the concentration of the active ingredient or extending the dosing interval to improve patient adherence/compliance. This review will focus on the history and progression of bromfenac ophthalmic solution and report the available patient preference and adherence data regarding this ocular NSAID throughout its evolution.
Acknowledgments
The authors wish to acknowledge the following contributions: Michelle Dalton, BS, ELS, for her medical writing; and Mauricio Munoz, PharmD, and Linda Wang, PharmD, for data review, verification, and editorial assistance.
Disclosure
Bausch + Lomb provided financial assistance and editorial support in the preparation of this manuscript. RR is a consultant for Bausch + Lomb. The authors report no other conflicts of interest in this work.